Dexmedetomidine vs Propofol in High-Risk ERCP Patients

NARecruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 3, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

January 15, 2026

Conditions
Respiratory DepressionHypoxemiaHypotension Drug-InducedBradycardia
Interventions
DRUG

dexmedetomidin

Dexmedetomidine is a highly selective α2-adrenergic receptor agonist with sedative, anxiolytic, and analgesic properties. Unlike many other sedatives, it provides sedation without significant respiratory depression, though it may cause bradycardia and hypotension

DRUG

Propofol

Propofol is a short-acting intravenous anesthetic agent widely used for induction and maintenance of anesthesia as well as procedural sedation. It provides rapid onset and recovery, but is associated with respiratory depression and hypotension

Trial Locations (1)

34371

RECRUITING

Sisli etfal research and training hospital, Sarıyer

All Listed Sponsors
lead

Sisli Hamidiye Etfal Training and Research Hospital

OTHER

NCT07166614 - Dexmedetomidine vs Propofol in High-Risk ERCP Patients | Biotech Hunter | Biotech Hunter